Novavax's COVID and Flu Vaccine Candidates Show Strong Promise in Trials and Boost Stock by 51%.
TL;DR Summary
Novavax's stock rose by 51% after the biotech company announced positive results from a trial of three flu and COVID vaccines and a restructuring plan that includes laying off 25% of its workforce. The company's stock had previously been affected by concerns raised by its "going-concern" warning earlier this year.
- Novavax’s stock soars 51% after positive COVID and flu trial data and layoff news MarketWatch
- Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses PR Newswire
- Novavax's COVID, flu vaccine candidates show promise in study Reuters
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
0 min
vs 1 min read
Condensed
57%
117 → 50 words
Want the full story? Read the original article
Read on MarketWatch